HURA

Company Overview — What Does TuHURA Biosciences, Inc./NV Do?

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. TuHURA Biosciences, Inc./NV (HURA) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO James Bianco. With a market capitalization of $91M, HURA is one of the notable companies in the Healthcare sector.

TuHURA Biosciences, Inc./NV (HURA) Stock Rating — Avoid (April 2026)

As of April 2026, TuHURA Biosciences, Inc./NV receives a Avoid rating with a composite score of 22.6/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.HURA ranks #3,933 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, TuHURA Biosciences, Inc./NV ranks #673 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

HURA Stock Price and 52-Week Range

TuHURA Biosciences, Inc./NV (HURA) currently trades at $2.24. The stock gained $0.28 (14.3%) in the most recent trading session. The 52-week high for HURA is $4.44, which means the stock is currently trading -49.6% from its annual peak. The 52-week low is $0.41, putting the stock 446.3% above its annual trough. Recent trading volume was 1.9M shares, reflecting moderate market activity.

Is HURA Overvalued or Undervalued? — Valuation Analysis

TuHURA Biosciences, Inc./NV (HURA) carries a value factor score of 24/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 4.48x, versus the sector average of 2.75x.

At current multiples, TuHURA Biosciences, Inc./NV trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

TuHURA Biosciences, Inc./NV Profitability — ROE, Margins, and Quality Score

TuHURA Biosciences, Inc./NV (HURA) earns a quality factor score of 12/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -120.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -92.5% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

HURA Debt, Balance Sheet, and Financial Health

TuHURA Biosciences, Inc./NV has a debt-to-equity ratio of 31.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 0.78x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $493,386. Cash and equivalents stand at $3M.

HURA has a beta of 1.40, meaning it is more volatile than the broader market — a $10,000 investment in HURA would be expected to move 40.3% more than the S&P 500 on any given day. The stability factor score for TuHURA Biosciences, Inc./NV is 15/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

TuHURA Biosciences, Inc./NV Revenue and Earnings History — Quarterly Trend

In TTM 2026, TuHURA Biosciences, Inc./NV reported revenue of $0 and earnings per share (EPS) of $-0.63. Net income for the quarter was $-25M. Operating income came in at $-2M.

In FY 2025, TuHURA Biosciences, Inc./NV reported revenue of $0 and earnings per share (EPS) of $-0.63. Net income for the quarter was $-30M.

In Q3 2025, TuHURA Biosciences, Inc./NV reported revenue of $0 and earnings per share (EPS) of $-0.14. Net income for the quarter was $-7M.

In Q2 2025, TuHURA Biosciences, Inc./NV reported revenue of $0 and earnings per share (EPS) of $-0.21. Net income for the quarter was $-10M.

Over the past 8 quarters, TuHURA Biosciences, Inc./NV has experienced revenue contraction from $0 to $0. Investors analyzing HURA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

HURA Dividend Yield and Income Analysis

TuHURA Biosciences, Inc./NV (HURA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

HURA Momentum and Technical Analysis Profile

TuHURA Biosciences, Inc./NV (HURA) has a momentum factor score of 27/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 49/100 reflects moderate short selling activity.

HURA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, TuHURA Biosciences, Inc./NV (HURA) ranks #673 out of 838 stocks based on the Blank Capital composite score. This places HURA in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing HURA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full HURA vs S&P 500 (SPY) comparison to assess how TuHURA Biosciences, Inc./NV stacks up against the broader market across all factor dimensions.

HURA Next Earnings Date

No upcoming earnings date has been announced for TuHURA Biosciences, Inc./NV (HURA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy HURA? — Investment Thesis Summary

The quantitative profile for TuHURA Biosciences, Inc./NV suggests caution. The quality score of 12/100 flags below-average profitability. The value score of 24/100 indicates premium valuation. Momentum is weak at 27/100, a headwind for near-term performance. High volatility (stability score 15/100) increases portfolio risk.

In summary, TuHURA Biosciences, Inc./NV (HURA) earns a Avoid rating with a composite score of 22.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on HURA stock.

Related Resources for HURA Investors

Explore more research and tools: HURA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare HURA head-to-head with peers: HURA vs AZN, HURA vs SLGL, HURA vs VMD.